Trimodality Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer

Authors:
Ronald C. ChenFrom the Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, and Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Search for other papers by Ronald C. Chen in
Current site
Google Scholar
PubMedClose
 MD, MPH
,
William U. ShipleyFrom the Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, and Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Search for other papers by William U. Shipley in
Current site
Google Scholar
PubMedClose
 MD
,
Jason A. EfstathiouFrom the Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, and Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Search for other papers by Jason A. Efstathiou in
Current site
Google Scholar
PubMedClose
 MD, PhD
, and
Anthony L. ZietmanFrom the Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, and Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Search for other papers by Anthony L. Zietman in
Current site
Google Scholar
PubMedClose
 MD
Volume/Issue:
Volume 11: Issue 8
Online Publication Date:
Aug 2013
DOI:
https://doi.org/10.6004/jnccn.2013.0116
Restricted access

Potentially curative treatments for patients with muscle-invasive bladder cancer (MIBC) are underused, especially in the elderly. Trimodality bladder preservation therapy, which includes a maximally safe transurethral resection of the bladder tumor, followed by concurrent chemoradiation, fulfills this currently unmet need. In multiple prospective clinical trials and large institutional series, trimodality therapy has demonstrated excellent 5-year overall survival rates of 48% to 65%, comparable to those reported in cystectomy studies. Approximately 75% to 80% of long-term survivors maintain their native bladders, which tend to function well and allow patients to maintain excellent quality of life. Salvage cystectomy for patients who develop a local invasive recurrence can be performed with acceptable operative complication rates, and results in excellent long-term disease control and survival outcomes. For patients with MIBC who are noncystectomy candidates, or select patients who are motivated to keep their native bladders, trimodality bladder preservation therapy is recognized by the International Consultation on Urological Diseases-European Association of Urology and the NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer as an effective alternative to radical cystectomy, and should be considered. In the future, biomarkers may allow improved selection of patients for whom trimodality bladder preservation therapy is most likely to succeed.

Correspondence: Ronald C. Chen, MD, MPH, Department of Radiation Oncology, University of North Carolina at Chapel Hill, 101 Manning Drive, CB 7512, Chapel Hill, NC 27599-7512. E-mail: ronald_chen@med.unc.edu
  • Collapse
  • Expand
  • 1.

    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10–29.

  • 2.

    Gray P, Fedewa S, Shipley W et al.. Use of potentially curative therapies for muscle-invasive bladder cancer in the united states: results from the National Cancer Data Base. Eur Urol 2013;63:823–829.

    • Search Google Scholar
    • Export Citation
  • 3.

    Lund L, Jacobsen J, Clark P et al.. Impact of comorbidity on survival of invasive bladder cancer patients, 1996-2007: a Danish population-based cohort study. Urology 2010;75:393–398.

    • Search Google Scholar
    • Export Citation
  • 4.

    Megwalu II, Vlahiotis A, Radwan M et al.. Prognostic impact of comorbidity in patients with bladder cancer. Eur Urol 2008;53:581–589.

  • 5.

    Clark PE, Agarwal N, Eisenberger MA et al.. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 1, 2013. Available at: NCCN.org. Accessed July 10, 2013.

    • Search Google Scholar
    • Export Citation
  • 6.

    Gakis G, Efstathiou J, Lerner SP et al.. ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2013;63:45–57.

    • Search Google Scholar
    • Export Citation
  • 7.

    Froehner M, Brausi MA, Herr HW et al.. Complications following radical cystectomy for bladder cancer in the elderly. Eur Urol 2009;56:443–454.

  • 8.

    Donat SM, Shabsigh A, Savage C et al.. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol 2009;55:177–185.

    • Search Google Scholar
    • Export Citation
  • 9.

    Liberman D, Lughezzani G, Sun M et al.. Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder. Urology 2011;77:660–666.

    • Search Google Scholar
    • Export Citation
  • 10.

    Kaufman DS, Shipley WU, Griffin PP et al.. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 1993;329:1377–1382.

    • Search Google Scholar
    • Export Citation
  • 11.

    Mak R, Hunt D, Shipley W et al.. Long-term outcomes in patients with muscle-invasive bladder cancer after bladder-preserving combined-modality therapy: a pooled analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233 [abstract]. J Clin Oncol 2012;30(Suppl 5):Abstract 264.

    • Search Google Scholar
    • Export Citation
  • 12.

    Efstathiou JA, Spiegel DY, Shipley WU et al.. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012;61:705–711.

    • Search Google Scholar
    • Export Citation
  • 13.

    Rödel C, Grabenbauer GG, Kühn R et al.. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002;20:3061–3071.

    • Search Google Scholar
    • Export Citation
  • 14.

    Perdonà S, Autorino R, Damiano R et al.. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. Cancer 2008;112:75–83.

    • Search Google Scholar
    • Export Citation
  • 15.

    James ND, Hussain SA, Hall E et al.. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012;366:1477–1488.

    • Search Google Scholar
    • Export Citation
  • 16.

    Shipley WU, Winter KA, Kaufman DS et al.. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998;16:3576–3583.

    • Search Google Scholar
    • Export Citation
  • 17.

    Efstathiou JA, Shipley WU. Words of wisdom. Re: radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. Eur Urol 2013;63:181–182.

    • Search Google Scholar
    • Export Citation
  • 18.

    Hussain SA, Moffitt DD, Glaholm JG et al.. A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer. Ann Oncol 2001;12:929–935.

    • Search Google Scholar
    • Export Citation
  • 19.

    Kent E, Sandler H, Montie J et al.. Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial. J Clin Oncol 2004;22:2540–2545.

    • Search Google Scholar
    • Export Citation
  • 20.

    Choudhury A, Swindell R, Logue JP et al.. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol 2011;29:733–738.

    • Search Google Scholar
    • Export Citation
  • 21.

    Grossman HB, Natale RB, Tangen CM et al.. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859–866.

    • Search Google Scholar
    • Export Citation
  • 22.

    Zehnder P, Studer UE, Skinner EC et al.. Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol 2011;186:1261–1268.

    • Search Google Scholar
    • Export Citation
  • 23.

    Gray PJ, Fedewa SA, Shipley WU et al.. Clinical-pathologic stage discrepancy in patients with bladder cancer treated with radical cystectomy: associations with clinical variables and survival [abstract]. J Clin Oncol 2013;31(Suppl 6):Abstract 248.

    • Search Google Scholar
    • Export Citation
  • 24.

    Malmström PU, Rintala E, Wahlqvist R et al.. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 1996;155:1903–1906.

    • Search Google Scholar
    • Export Citation
  • 25.

    Sherif A, Rintala E, Mestad O et al.. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer—Nordic Cystectomy Trial 2. Scand J Urol Nephrol 2002;36:419–425.

    • Search Google Scholar
    • Export Citation
  • 26.

    Kaufman DS, Winter KA, Shipley WU et al.. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 2000;5:471–476.

    • Search Google Scholar
    • Export Citation
  • 27.

    Kaufman DS, Winter KA, Shipley WU et al.. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 2009;73:833–837.

    • Search Google Scholar
    • Export Citation
  • 28.

    Hagan MP, Winter KA, Kaufman DS et al.. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 2003;57:665–672.

    • Search Google Scholar
    • Export Citation
  • 29.

    Efstathiou JA, Bae K, Shipley WU et al.. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 2009;27:4055–4061.

    • Search Google Scholar
    • Export Citation
  • 30.

    Zapatero A, García-Vicente F, Martín de Vidales C et al.. Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease? Int J Radiat Oncol Biol Phys 2011;81:1279–1285.

    • Search Google Scholar
    • Export Citation
  • 31.

    Lagrange JL, Bascoul-Mollevi C, Geoffrois L et al.. Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015). Int J Radiat Oncol Biol Phys 2011;79:172–178.

    • Search Google Scholar
    • Export Citation
  • 32.

    Zietman AL, Sacco D, Skowronski U et al.. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol 2003;170:1772–1776.

    • Search Google Scholar
    • Export Citation
  • 33.

    Housset M, Maulard C, Chretien Y et al.. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993;11:2150–2157.

    • Search Google Scholar
    • Export Citation
  • 34.

    Eswara JR, Efstathiou JA, Heney NM et al.. Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. J Urol 2012;187:463–468.

    • Search Google Scholar
    • Export Citation
  • 35.

    Tester W, Caplan R, Heaney J et al.. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 1996;14:119–126.

    • Search Google Scholar
    • Export Citation
  • 36.

    Zapatero A, Martin de Vidales C, Arellano R et al.. Updated results of bladder-sparing trimodality approach for invasive bladder cancer. Urol Oncol 2010;28:368–374.

    • Search Google Scholar
    • Export Citation
  • 37.

    Fung CY, Shipley WU, Young RH et al.. Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy. J Clin Oncol 1991;9:1533–1542.

    • Search Google Scholar
    • Export Citation
  • 38.

    Choudhury A, Nelson LD, Teo MT et al.. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res 2010;70:7017–7026.

    • Search Google Scholar
    • Export Citation
  • 39.

    Laurberg JR, Brems-Eskildsen AS, Nordentoft I et al.. Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer. BJU Int 2012;110:E1228–1236.

    • Search Google Scholar
    • Export Citation
  • 40.

    Mitin T, Hunt D, Shipley WU et al.. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol, in press.

    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2013 by the National Comprehensive Cancer Network 2013
Page Numbers:
9
Article Category:
Research Article
Received:
18 Dec 2012
Accepted:
26 Apr 2013
Print Publication Date:
01 Aug 2013
Online Publication Date:
Aug 2013
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1290 299 22
PDF Downloads 624 219 22
EPUB Downloads 0 0 0